Skip to Main Content

INFORMATION FOR

Nicholas Blondin, MD

Assistant Professor

Contact Information

Nicholas Blondin, MD

Office Location

Mailing Address

  • Yale Cancer Center

    5520 Park Avenue

    Trumbull, CT 06611

    United States

Research Summary

Dr. Blondin is an active investigator for clinical trials for brain tumor patients through Yale Cancer Center.

Extensive Research Description

Dr. Blondin is an active investigator for clinical trials for brain tumor patients through Yale Cancer Center.

Coauthors

Research Interests

Nervous System Neoplasms; Neurology

Selected Publications

Clinical Trials

ConditionsStudy Title
Brain and Nervous SystemA Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma
Brain and Nervous SystemPhase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Brain and Nervous SystemA Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma
Brain and Nervous System; PediatricsA Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Brain and Nervous SystemGBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Brain and Nervous SystemGenomically-Guided Treatment Trial in Brain Metastases
Brain and Nervous SystemPhase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Brain and Nervous SystemPhase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Brain and Nervous SystemPhase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Brain and Nervous SystemAn Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)